Eye institute and Dainippon to develop iPS cell-based therapies

04/1/2013 | Genetic Engineering & Biotechnology News

Retina Institute Japan will receive about $16 million in an investment from Dainippon Sumitomo Pharma as part of a deal to work on new induced pluripotent stem cell-based therapies. The investment will give Dainippon a 5% stake in the institute. The partnership's focus will include treatments for refractory retinal disease and age-related macular degeneration.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY